Literature DB >> 28700444

Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Mohammad A Al Efishat1, Marc A Attiyeh1, Anne A Eaton2, Mithat Gönen2, Denise Prosser3, Anna E Lokshin3, Carlos Fernández-Del Castillo4, Keith D Lillemoe4, Cristina R Ferrone4, Ilaria Pergolini4, Mari Mino-Kenudson5, Neda Rezaee6, Marco Dal Molin6, Matthew J Weiss6, John L Cameron6, Ralph H Hruban7, Michael I D'Angelica1, T Peter Kingham1, Ronald P DeMatteo1, William R Jarnagin1, Christopher L Wolfgang6, Peter J Allen1.   

Abstract

OBJECTIVE: Preliminary work by our group suggested that proteins within the pancreatic cyst fluid (CF) may discriminate degree of IPMN dysplasia. We sought to externally validate these markers and determine whether their inclusion in a preoperative clinical nomogram could increase diagnostic accuracy. SUMMARY BACKGROUND DATA: IPMN is the most common radiographically identifiable precursor to pancreatic cancer; however, the timing and frequency of its malignant progression are unknown, and there are currently no reliable preoperative tests that can determine the grade of dysplasia in IPMN.
METHODS: Clinical and radiographic data, as well as CF samples, were obtained from 149 patients who underwent resection for IPMN at 1 of 3 institutions. High-risk disease was defined as the presence of high-grade dysplasia or invasive carcinoma. Multianalyte bead array analysis (Luminex) of CF was performed for 4 protein markers that were previously associated with high-risk disease. Logistic regression models were fit on training data, with and without adjustment for a previously developed clinical nomogram and validated with an external testing set. The models incorporating clinical risk score were presented graphically as nomograms.
RESULTS: Within the group of 149 resected patients, 89 (60%) had low-risk disease, and 60 (40%) had high-risk disease. All 4 CF markers (MMP9, CA72-4, sFASL, and IL-4) were overexpressed in patients with high-risk IPMN (P < 0.05). Two predictive models based on preselected combinations of CF markers had concordance indices of 0.76 (Model-1) and 0.80 (Model-2). Integration of each CF marker model into a previously described clinical nomogram leads to increased discrimination compared with either the CF models or nomogram alone (c-indices of 0.84 and 0.83, respectively).
CONCLUSIONS: This multi-institutional study validated 2 CF protein marker models for preoperative identification of high-risk IPMN. When combined with a clinical nomogram, the ability to predict high-grade dysplasia was even stronger.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28700444      PMCID: PMC5764837          DOI: 10.1097/SLA.0000000000002421

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  46 in total

1.  Evaluation of cyst fluid CEA analysis in the diagnosis of mucinous cysts of the pancreas.

Authors:  Satish Nagula; Timothy Kennedy; Mark A Schattner; Murray F Brennan; Hans Gerdes; Arnold J Markowitz; Laura Tang; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2010-07-24       Impact factor: 3.452

2.  Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Ajay V Maker; Nora Katabi; Mithat Gonen; Ronald P DeMatteo; Michael I D'Angelica; Yuman Fong; William R Jarnagin; Murray F Brennan; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2010-08-18       Impact factor: 5.344

Review 3.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

4.  Cytology from pancreatic cysts has marginal utility in surgical decision-making.

Authors:  Ajay V Maker; Linda S Lee; Chandrajit P Raut; Thomas E Clancy; Richard S Swanson
Journal:  Ann Surg Oncol       Date:  2008-09-03       Impact factor: 5.344

5.  Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm.

Authors:  Christopher J DiMaio; Frances Weis-Garcia; Emilia Bagiella; Laura H Tang; Peter J Allen
Journal:  Gastrointest Endosc       Date:  2015-09-25       Impact factor: 9.427

6.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection.

Authors:  Giovanni Marchegiani; Mari Mino-Kenudson; Klaus Sahora; Vicente Morales-Oyarvide; Sarah Thayer; Cristina Ferrone; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-Del Castillo
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

8.  Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm.

Authors:  Peter J Allen; Li-Xuan Qin; Laura Tang; David Klimstra; Murray F Brennan; Anna Lokshin
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

9.  Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy.

Authors:  Nicole A Belsley; Martha B Pitman; Gregory Y Lauwers; William R Brugge; Vikram Deshpande
Journal:  Cancer       Date:  2008-04-25       Impact factor: 6.860

10.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  18 in total

Review 1.  Molecular Diagnostics and Testing for Pancreatic Cysts.

Authors:  Jaime de la Fuente; Shounak Majumder
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-27

2.  Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance.

Authors:  Masaya Suenaga; Jun Yu; Koji Shindo; Koji Tamura; Jose Alejandro Almario; Christopher Zaykoski; P Dane Witmer; Shahriar Fesharakizadeh; Michael Borges; Anne-Marie Lennon; Eun-Ji Shin; Marcia Irene Canto; Michael Goggins
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

Review 3.  The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?

Authors:  Jenny Lim; Peter J Allen
Journal:  Updates Surg       Date:  2019-06-07

4.  Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Authors:  Rachel E Simpson; Michele T Yip-Schneider; Katelyn F Flick; Huangbing Wu; Cameron L Colgate; C Max Schmidt
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

5.  Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis.

Authors:  Marc A Attiyeh; Jayasree Chakraborty; Lior Gazit; Liana Langdon-Embry; Mithat Gonen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Peter J Allen; Richard K Do; Amber L Simpson
Journal:  HPB (Oxford)       Date:  2018-08-07       Impact factor: 3.647

6.  Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.

Authors:  Ajay V Maker; Vincent Hu; Shrihari S Kadkol; Lenny Hong; William Brugge; Jordan Winter; Charles J Yeo; Thilo Hackert; Markus Büchler; Rita T Lawlor; Roberto Salvia; Aldo Scarpa; Claudio Bassi; Stefan Green
Journal:  J Am Coll Surg       Date:  2019-02-19       Impact factor: 6.113

7.  Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms.

Authors:  Kate A Harrington; Travis L Williams; Sharon A Lawrence; Jayasree Chakraborty; Mohammad A Al Efishat; Marc A Attiyeh; Gokce Askan; Yuting Chou; Alessandra Pulvirenti; Caitlin A McIntyre; Mithat Gonen; Olca Basturk; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; William R Jarnagin; Jeffrey A Drebin; Richard K Do; Peter J Allen; Amber L Simpson
Journal:  J Med Imaging (Bellingham)       Date:  2020-06-25

8.  Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing.

Authors:  Shounak Majumder; William R Taylor; Tracy C Yab; Calise K Berger; Brian A Dukek; Xiaoming Cao; Patrick H Foote; Chung Wah Wu; Douglas W Mahoney; Harry R Aslanian; Carlos Fernández-Del Castillo; Leona A Doyle; James J Farrell; William E Fisher; Linda S Lee; Yvonne N Lee; Walter Park; Clifton Rodrigues; Bonnie Elyssa Gould Rothberg; Ronald R Salem; Diane M Simeone; Sumithra Urs; George Van Buren; Thomas C Smyrk; Hatim T Allawi; Graham P Lidgard; Massimo Raimondo; Suresh T Chari; Michael L Kendrick; John B Kisiel; Mark D Topazian; David A Ahlquist
Journal:  Am J Gastroenterol       Date:  2019-09       Impact factor: 10.864

Review 9.  Narrative review of intraductal papillary mucinous neoplasms: pathogenesis, diagnosis, and treatment of a true precancerous lesion.

Authors:  Gang Ma; Guichen Li; Zhihuan Xiao; Anjiang Gou; Yuanhong Xu; Shaowei Song; Kejian Guo; Zhe Liu
Journal:  Gland Surg       Date:  2021-07

Review 10.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.